In the 100+ features we published this year, MedTech Strategist brought you in-depth explorations of global medical device industry trends and strategies for capitalizing on them; one-on-one interviews with industry leaders, innovators and investors; and profiles of cutting-edge medtech start-ups. Herein, a look at our most-read, most-discussed articles in 2019.
It’s been an exciting year at MedTech Strategist. We launched a sister publication, Market Pathways: Global Medical Device Regulatory, Reimbursement & Policy Review in June. In August, we unveiled our new web platform MyStrategist.com, which makes it easier than ever for you to find our peerless analysis and insights about the global medical device industry. Pay us a visit today and sign up to receive our free, informative emails when new content posts in any of our publications, including our popular Community Blog.
Strategy & Innovation
These initiatives have not distracted us from our flagship product, MedTech Strategist. For decades, our editorial team has enjoyed unrivaled access to leaders of the medical device industry. Our close relationships with medtech executives and innovators allow us to dig into the forces that motivate and drive them, and the factors that shape their strategic decision-making. As always, our conversations with these movers and shakers and our deep dives into the ventures they create were a big part of our offering in 2019. Among the articles that resonated with MedTech Strategist readers:
Accelerated M&A, targeted investments, and innovative collaborations are among the strategies that new devices EVP Ashley McEvoy is pursuing to bring J&J’s medtech mojo back.
Intuitive Surgical has long dominated the field surgical robotics, but it is now facing serious competition from medtech giants as well as numerous start-ups. This increased competition comes at a time when the very nature of robotically-enabled surgery is changing due to the advent of advanced digital technologies.
Former Edwards CSO and TAVR pioneer Stan Rowe is teaming up with deep-pocketed Deerfield Management to create a new innovation center that solves the problem most medical device incubators face: finding sufficient capital to survive early development efforts.
What does it take to be a successful medtech innovator and bring compelling device technologies to market? Read our two-part candid, free-wheeling conversation with four of the industry’s top physician-entrepreneurs: Billy Cohn, Howard Levin, Josh Makower, and Martin Rothman.
The thoroughness that our team brings to executive interviews and company-focused stories applies to our coverage of clinical areas. We reported on new technologies and business developments across a broad swath of clinical markets throughout 2019. Here, a sampling of our most-read work:
Now the most common type of failure, heart failure with preserved ejection fraction (HFpEF) offers an emerging device opportunity at the intersection of two high growth medical device markets: heart failure and structural heart.
Treating diseases of the deep veins has been an innovation backwater, but things are changing. The first venous stents were approved in 2019, and several start-ups are addressing unmet clinical needs with devices purposely built for veins, not borrowed from the arterial side of the anatomy.
Part of our popular “Technologies to Watch” series, this article explored the continued high-tech transformation of the diabetes device market as companies work to roll out new, more patient-friendly devices.
For 50 years, JDRF has been a staunch supporter of, early-stage research into treatments for type 1 diabetes. JDRF has now sponsored its own venture investment vehicle—the JDRF T1D Fund— which is focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes through catalytic commercial investment.
An ever-growing roster of new, more effective drugs has driven precision medicine, but the ability to determine the best treatments for an individual requires the use of sophisticated devices and diagnostics. The most advances have been made in oncology, where meticulous collection and preservation of tissue biopsies are keys to matching patients with the right drugs.
Miach’s tissue-engineered approach to ACL reconstruction mirrors a larger trend in medical device development away from mechanical approaches toward biological ones.
OrthoPediatrics is building a leadership position in a niche overlooked by most of the orthopedic industry. The company’s recent acquisition of Vilex shows its growing confidence, and also underscores the necessity of a “stick-to-the-knitting” strategy in a field that many believe has limited potential.
Revascularization rates in acute ischemic stroke are 85-95%, but only after many passes with mechanical thrombectomy devices. Companies and clinicians are working to increase first pass success rates because clinical trials suggest that outcomes are better when the occluded artery can be opened on the first try.
As healthcare consumers increasingly demand and seek out more convenient, tech-enabled care—and the data they and their providers collect grows in importance—medtech companies will have many opportunities to capitalize. But doing so successfully will require a good deal of flexibility, leadership, and culture change. We pointed the way in several of our 2019 feature articles. These two pieces in particular sparked readers’ interest.
Medtech companies who want to position themselves as innovative market leaders in these changing times need to re-think the status-quo, adopting a more consumer-centric, tech-like approach to product design; collaborating when necessary; and pushing for more flexibility and agility in the product development and regulatory processes.
Primary care is emerging as the major battleground in the shift to digitally-enabled, consumer-centric healthcare with a focus on prevention and wellness rather than sick care. This upheaval creates create both challenges and opportunities for medtechs. Large new markets will emerge, but the future product mix (and the competitive environment) is likely to look very different than it does today.